301207 logo

Hualan Biological Vaccine XSEC:301207 Stock Report

Last Price

CN¥21.98

Market Cap

CN¥13.2b

7D

-5.7%

1Y

-32.7%

Updated

30 Apr, 2024

Data

Company Financials +

Hualan Biological Vaccine Inc.

XSEC:301207 Stock Report

Market Cap: CN¥13.2b

301207 Stock Overview

Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China.

301207 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance4/6
Financial Health5/6
Dividends4/6

Hualan Biological Vaccine Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hualan Biological Vaccine
Historical stock prices
Current Share PriceCN¥21.98
52 Week HighCN¥36.50
52 Week LowCN¥19.16
Beta0.76
1 Month Change-7.96%
3 Month Change0.96%
1 Year Change-32.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO-36.89%

Recent News & Updates

Recent updates

Shareholder Returns

301207CN BiotechsCN Market
7D-5.7%3.5%4.4%
1Y-32.7%-22.5%-12.6%

Return vs Industry: 301207 underperformed the CN Biotechs industry which returned -22.5% over the past year.

Return vs Market: 301207 underperformed the CN Market which returned -12.6% over the past year.

Price Volatility

Is 301207's price volatile compared to industry and market?
301207 volatility
301207 Average Weekly Movement6.4%
Biotechs Industry Average Movement8.0%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 301207 has not had significant price volatility in the past 3 months.

Volatility Over Time: 301207's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005770Wenjue Anwww.hualanbacterin.com

Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China.

Hualan Biological Vaccine Inc. Fundamentals Summary

How do Hualan Biological Vaccine's earnings and revenue compare to its market cap?
301207 fundamental statistics
Market capCN¥13.19b
Earnings (TTM)CN¥804.59m
Revenue (TTM)CN¥2.30b

16.4x

P/E Ratio

5.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301207 income statement (TTM)
RevenueCN¥2.30b
Cost of RevenueCN¥385.74m
Gross ProfitCN¥1.91b
Other ExpensesCN¥1.11b
EarningsCN¥804.59m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.34
Gross Margin83.23%
Net Profit Margin34.98%
Debt/Equity Ratio4.8%

How did 301207 perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

45%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.